ReviewCells2023
Sex Differences in Therapies against Myocardial Ischemia-Reperfusion Injury: From Basic Science to Clinical Perspectives.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Post-PCI outcomes in women with acute coronary syndrome: a systematic review and meta-analysis of risk factors.BMC cardiovascular disorders · 2026Pooled it
- Protective effect of salvianolic acid B against myocardial ischemia/reperfusion injury: preclinical systematic evaluation and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Review
- Novel model to predict survival in DCD heart transplants: Development of a mortality risk score using UNOS data.JHLT open · 2026Article
- Gender- and sex-dependent variations in heart failure and cardiomyopathies: a review of the literature.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Differences in mortality by donor sex and age in heart transplantation: An individual patient data meta-analysis.JHLT open · 2026Article
- Cardioprotective Signaling: Outline and Future Directions.Biomedicines · 2025Review
- Temporal and Spatial Dynamics in the Regulation of Myocardial Metabolism During the Ischemia-Reperfusion Process.International journal of molecular sciences · 2025Article
- Sex-based disparities in dopamine agonist response in patients with restless legs syndrome.Journal of sleep research · 2025Article
- The Development of a Nomogram Predictive Model for Intracardiac Thrombosis Risk: A Study Based on Risk Factors in Patients with Acute Myocardial Infarction.Biomedicines · 2025Article
- Testosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow.Nature communications · 2025Article
- Article
- Specificities of Myocardial Infarction and Heart Failure in Women.Journal of clinical medicine · 2024Review
- Female cardioprotection in ischemia/reperfusion: Isn't a SUR thing anymore?Journal of molecular and cellular cardiology plus · 2024Article
- The Biological Mechanisms and Clinical Roles of RNA-Binding Proteins in Cardiovascular Diseases.Biomolecules · 2024Review
- Article
- Effect of long-term inorganic nitrate administration on myocardial ischemia-reperfusion injury in ovariectomized rats.Frontiers in pharmacology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mortality from myocardial infarction (MI) has declined over recent decades, which could be attributed in large part to improved treatment methods. Early reperfusion is the cornerstone of current MI treatment. However, reoxygenation via restored blood flow induces further damage to the myocardium, leading to ischemia-reperfusion injury (IRI). While experimental studies overwhelmingly demonstrate that females experience greater functional recovery from MI and decreased severity in the underlying pathophysiological mechanisms, the outcomes of MI with subsequent reperfusion therapy, which is the clinical correlate of myocardial IRI, are generally poorer for women compared with men. Distressingly, women are also reported to benefit less from current guideline-based therapies compared with men. These seemingly contradicting outcomes between experimental and clinical studies show a need for further investigation of sex-based differences in disease pathophysiology, treatment response, and a sex-specific approach in the development of novel therapeutic methods against myocardial IRI. In this literature review, we summarize the current knowledge on sex differences in the underlying pathophysiological mechanisms of myocardial IRI, including the roles of sex hormones and sex chromosomes. Furthermore, we address sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics of current drugs prescribed to limit myocardial IRI. Lastly, we highlight ongoing clinical trials assessing novel pharmacological treatments against myocardial IRI and sex differences that may underlie the efficacy of these new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.